Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA AG    MRK   DE0006599905

MERCK KGAA AG

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : sees currencies supporting 2019 outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2019 | 06:57am EDT
A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt

FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth this year.

Merck on Tuesday confirmed its guidance for an underlying increase of 10-13% in 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA) and adjusted for one-off items but now sees a positive effect of 0% to +2% from currencies.

It had previously seen a 3-4% drag from foreign exchange effects.

First-quarter EBITDA, adjusted for special items, slipped 4% to 929 million euros (806 million pounds), below the average analyst estimate of 944 million in a Reuters poll.

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA AG 0.82% 96.2 Delayed Quote.6.91%
VERSUM MATERIALS INC 0.04% 52.05 Delayed Quote.87.70%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA AG
08/19MERCK : Darmstadt, Germany Granted 20 CRISPR Patents Total Worldwide
PU
08/14PFIZER : Oncolytics Biotech Reports 2019 Second Quarter Financial Results and Op..
AQ
08/12No-deal Brexit could deepen Europe's shortage of medicines - experts
RE
08/08Merck KGaA's profit bolstered by lab supplies, drug milestone payments
RE
08/08MERCK : 2Q Net Profit Soared; Backs Outlook
DJ
08/06Merck KGaA Buys German Lab Data Company
DJ
08/05Merck KGaA to Collaborate With Universal Display Corp in OLED Research
DJ
07/31Agilent Says Companion Diagnostic Gets Expanded FDA Approval
DJ
07/30NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/30NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (EUR)
Sales 2019 15 619 M
EBIT 2019 2 199 M
Net income 2019 1 486 M
Debt 2019 6 035 M
Yield 2019 1,35%
P/E ratio 2019 27,9x
P/E ratio 2020 22,8x
EV / Sales2019 3,06x
EV / Sales2020 2,80x
Capitalization 41 713 M
Chart MERCK KGAA AG
Duration : Period :
Merck KGaA AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 102,22  €
Last Close Price 95,94  €
Spread / Highest target 27,2%
Spread / Average Target 6,54%
Spread / Lowest Target -14,5%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA AG6.91%46 286
WUXI APPTEC CO LTD43.09%17 662
KYOWA KIRIN CO LTD-8.83%9 429
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.48%8 378
JAZZ PHARMACEUTICALS PLC7.98%7 726
BETTA PHARMACEUTICALS CO LTD--.--%2 782